Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07132021

Efficacy of Trans-auricular Vagus Nerve Stimulation on Upper Extremity Motor Recovery in Stroke Survivors

The aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Federal University of Pernambuco

Recife, Pernambuco, 50670-901, Brazil

Location status: Recruiting

Location contact

DANIEL G DE MELO, MsC

CONTACT

[email protected]

81995173332 ext. + 55

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged between 18 and 75 years, with motor impairment in the upper extremity caused by unilateral ischemic or hemorrhagic stroke with stroke onset within the last five years.

Exclusion criteria

  • Patients with any contraindication to taVNS, peripheral upper extremity injuries, use of medication affecting cortical excitability in the past 3 months, use of botulinum toxin in the past 3 months, presence of any other neurological disorder, or significant cognitive deficits.

Treatment and study plan

Active taVNS

Device

Protocol uses a 25 Hz frequency with 500 μs pulse width in biphasic configuration, operating at a 1:1 duty cycle with current intensity set to the maximum tolerable level without inducing pain. The total stimulation duration is 60 minutes. The stimulation is combined with physical therapy focused on upper extremity function.

Sham taVNS

Device

Physical therapy focused on upper extremity function with masking for transcutaneous vagus nerve stimulation

Primary outcomes

  1. Upper extremity Motor Function (Fugl-Meyer Assessment - Upper Extremity)

    Time frame: Baseline (Day 0), mid-intervention (day 5) and post-intervention (day 10)

    The Fugl-Meyer Assessment for Upper Extremity (FMA-UE) will be used to evaluate motor impairment and recovery of the paretic upper extremity. It consists of items from sections III and IV, assessing motor function, coordination, and speed, with a maximum score of 66 points. Higher scores indicate lower motor impairment. A minimal clinically important difference (mCID) is defined as a change (Δ) of 5 or more points between baseline and post-intervention scores.

Secondary outcomes

  1. Manual Dexterity (Box and Block Test)

    Time frame: Baseline (Day 0), mid-intervention (day 5) and post-intervention (day 10)

    The Box and Block Test (BBT) will assess manual dexterity of the paretic upper extremity. It counts the number of wooden blocks (2.5 x 2.5 x 2.5 cm) transferred from one compartment to another over a central divider within one minute. The minimal detectable change (MDC) is defined as a difference of 5 blocks per minute.

  2. Independence (Functional Independence Measure)

    Time frame: Baseline (Day 0), mid-intervention (day 5) and post-intervention (day 10)

    The Functional Independence Measure (FIM) assesses the level of independence through motor and cognitive subscales. Each item is scored from 1 to 7. Total score classifications: complete dependence (18-45), moderate independence (46-99), and complete independence (100-126). The MDC is defined as 17 points for the motor section, 3 points for the cognitive section, and 22 points for the total score.

  3. Spasticity (Modified Ashworth Scale)

    Time frame: Baseline (Day 0), mid-intervention (day 5) and post-intervention (day 10)

    The Modified Ashworth Scale (MAS) will assess spasticity in finger, wrist, elbow, and shoulder flexors of the paretic upper extremity. It uses a 6-point scale (0 to 5) to quantify muscle tone. The minimal clinically important difference (mCID) is defined as a reduction of at least one point in spasticity score.

  4. Health-Related Quality of Life (Stroke-Specific Quality of Life Scale)

    Time frame: Baseline (day 0), mid-intervention (day 5), post-intervention (day 10)

    The Stroke-Specific Quality of Life Scale (SS-QOL) assesses stroke-related quality of life across 12 domains, using 49 items. Scores range from 49 to 245, with higher scores indicating better quality of life. The MDC is 4.7 points for the total score, 2.1 for the physical subscore, and 2.8 for the psychosocial subscore.

  5. Multidimensional Stroke Impact (Stroke Impact Scale)

    Time frame: Baseline (Day 0), mid-intervention (Day 5), post-intervention (Day 10)

    The Stroke Impact Scale (SIS) is a self-reported questionnaire assessing multiple consequences of stroke including strength, hand function, mobility, ADLs/IADLs, memory and thinking, communication, emotion, and social participation. It is designed to capture the broader impact of stroke on health and quality of life.

  6. Global Perception of Change (Patient Global Impression of Change)

    Time frame: Baseline (Day 0), mid-intervention (Day 5), post-intervention (Day 10)

    The Global Perception of Change Scale (also referred to as Patient Global Impression of Change - PGIC) assesses the participant's perceived improvement at post-intervention. It includes 7 options, ranging from "no change or condition worsened" to "a great deal better, considerable improvement that made all the difference". A higher value indicates a higher perceived improvement.

Study contacts

Contact information is provided by the study sponsor or research team.

DANIEL G DE MELO, MsC

CONTACT

[email protected]

+5581995173332 ext. +55

Gabriel Barreto, PhD

CONTACT

[email protected]

83996106134 ext. +55

Sponsors and collaborators

Lead sponsor

Universidade Federal de Pernambuco

Other

Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Ciência e Tecnologia de Pernambuco

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 20, 2025
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.